UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

Therapeutic advances in gastroenterology, 2019, Vol.12, p.1756284819878660-1756284819878660

2019

Volltextzugriff (PDF)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

British journal of cancer, 2015-09, Vol.113 (7), p.989-995

2015

Volltextzugriff (PDF)

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

European journal of cancer (1990), 2020-09, Vol.136, p.25-34

2020

Volltextzugriff (PDF)

Second-Line Chemotherapy With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI Regimen) in Patients With Advanced Small Bowel Adenocarcinoma After Failure of First-Line Platinum-Based Chemotherapy: A Multicenter AGEO Study

Cancer, 2011-04, Vol.117 (7), p.1422-1428

2011

Volltextzugriff (PDF)

Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

Cancer, 2011-04, Vol.117 (7), p.1422-1428

2011

Volltextzugriff (PDF)

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)

BMJ open, 2023-06, Vol.13 (6), p.e069973-e069973

2023

Volltextzugriff (PDF)

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-05, Vol.315 (17), p.1844

2016

Volltextzugriff (PDF)

A multicenter telemonitoring-telecare study with automatic assessment of physiological parameters and patient-reported outcomes in remote pancreatic cancer patients on mFOLFIRINOX: Interim technology report

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13617-e13617

2022

Volltextzugriff (PDF)

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

European journal of cancer (1990), 2023-08, Vol.189, p.112934-112934, Article 112934

2023

Volltextzugriff (PDF)

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

European journal of cancer (1990), 2023-08, Vol.189

2023

Volltextzugriff (PDF)

New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial

Annals of surgery, 2024-11, Vol.280 (5), p.734-744

2024

Volltextzugriff (PDF)

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

Digestive and liver disease, 2022-03, Vol.54 (3), p.324-330

2022

Volltextzugriff (PDF)

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

Quality of life research, 2016-07, Vol.25 (7), p.1713-1723

2016

Volltextzugriff (PDF)

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4019-4019

2019

Volltextzugriff (PDF)

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)

Journal of clinical oncology, 2019, Vol.37 (15, S)

2019

Volltextzugriff (PDF)

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

European journal of cancer (1990), 2014-12, Vol.50 (18), p.3116-3124

2014

Volltextzugriff (PDF)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BMC cancer, 2014-06, Vol.14 (1), p.441-441, Article 441

2014

Volltextzugriff (PDF)

Multiple peritoneal calcifying fibrous tumors revealed by ischemic colitis

Annals of diagnostic pathology, 2007-12, Vol.11 (6), p.460-463

2007

Volltextzugriff (PDF)

Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.370-370

2018

Volltextzugriff (PDF)

Cardiophrenic angle lymph node is an indicator of metastatic spread but not specifically peritoneal carcinomatosis in colorectal cancer patients Results of a prospective validation study in 91 patients

European journal of surgical oncology, 2016-06, Vol.42 (6), p.861-868

2016

Volltextzugriff (PDF)

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4107-4107

2018

Volltextzugriff (PDF)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

JAMA oncology, 2023-10, Vol.9 (10), p.1356

2023

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(32)
Male
(22)
Female
(20)
Oncology
(20)
Aged
(18)
Middle Aged
(17)
Adult
(15)
Life Sciences
(15)
Chemotherapy
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Treatment Outcome
(9)
Metastasis
(8)
Prognosis
(8)
Tumors
(8)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Gastroenterology & Hepatology
(7)
Metastases
(7)
Pancreatic Cancer
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Second-Line Chemotherapy With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI Regimen) in Patients With Advanced Small Bowel Adenocarcinoma After Failure of First-Line Platinum-Based Chemotherapy: A Multicenter AGEO Study

Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial

A multicenter telemonitoring-telecare study with automatic assessment of physiological parameters and patient-reported outcomes in remote pancreatic cancer patients on mFOLFIRINOX: Interim technology report

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study

New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19)

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

Multiple peritoneal calcifying fibrous tumors revealed by ischemic colitis

Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

Cardiophrenic angle lymph node is an indicator of metastatic spread but not specifically peritoneal carcinomatosis in colorectal cancer patients Results of a prospective validation study in 91 patients

Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX)

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial

Suchergebnisse filtern